<DOC>
	<DOCNO>NCT00108056</DOCNO>
	<brief_summary>This study examine safety twice-a-day dose regimen experimental drug Enzastaurin patient malignant glioma ( cancerous brain tumor ) take certain anti-seizure medicine . Enzastaurin may prevent formation new blood vessel tumor need grow . It show effect brain tumor animal patient recurrent glioma . This study see drug help patient gliomas much drug give . Patients 18 year age old malignant glioma recur standard therapy may eligible study . Candidates screen physical examination , blood urine test , magnetic resonance imaging ( MRI ) compute tomography ( CT ) scan , electrocardiogram . Participants divide two group patients-those take certain anti-seizure medications-in order determine anti-seizure medication alters way body handle Enzastaurin . Patients group divide different dose regimen : group take Enzastaurin day 3 week , follow twice day 3 week ; others group take drug twice day 3 week follow day 3 week . The medication take mouth every day . Treatment give 6-week cycle may continue 1 year unless tumor grow patient develops unacceptable drug side effect . In addition drug treatment , patient follow test procedure : - Medical history , physical , neurological examination every 3 week first cycle every 6 week . - MRI CT scan head start new cycle . MRI use magnetic field radio wave produce image body tissue organ . CT use x-rays provide 3-dimensional view part body study . For procedure , patient lie table slide cylindrical scanner . - Routine blood test every week first cycle every 3 week . - Electrocardiogram day 21 42 first cycle , take drug 30 minute 4 hour take drug . - Pharmacokinetic study within 3 day day 21 first cycle . Several blood sample draw measure level Enzastaurin . Patients take drug day blood sample draw morning dose 1 , 2 , 4 , 6 24 hour dose . Patients take drug twice day sample draw morning dose , 1 , 2 , 4 , 6 12 hour dose , 12 hour even dose . In addition , day 1 extra tube blood drawn time Enzastaurin dose 4 hour later . - Dynamic MRI spectroscopy PET . These test do help distinguish live tumor die tumor . The experience dynamic MRI spectroscopy standard MRI do time standard procedure . PET use radioactive substance show cellular activity specific tissue body . The patient give injection sugar solution radioactive isotope attach sugar molecule . A special camera detect radiation emit radioisotope , result image show much glucose use various part body . Because rapidly grow cell , tumor , take use glucose normal cell , test use show active tumor .</brief_summary>
	<brief_title>Enzastaurin Treat Recurrent Brain Tumor</brief_title>
	<detailed_description>BACKGROUND : Enzastaurin macrocyclic bisindolylmaleimide disrupts intrinsic phosphotransferase activity conventional novel PKC isoforms via interaction ATP binding site , display selectivity inhibit isoforms . Preclinical study demonstrate potent anti-angiogenic activity enzastaurin study normal volunteer solid tumor patient demonstrate drug well tolerated dos achieve biologically active serum concentration . OBJECTIVES : To establish maximally tolerate dose enzastaurin patient refractory primary brain tumor enzyme-inducing anti-epileptic drug ( EIAED ) patient EIAEDs . To determine twice day dose result higher systemic exposure enzastaurin metabolite day dose patient EIAEDs EIAEDs . To obtain exploratory data regard relationship activity PKC-b pathway ( specifically GSK3-b activation ) peripheral blood mononuclear cell treat patient clinical outcome . To obtain exploratory information anti-tumor activity enzastaurin high dos specify protocol . ELIGIBILITY : Patients histologically prove malignant glioma eligible protocol . DESIGN : Patients stratify Group A Group B base concomitant medication . Patients enzyme induce anti-epileptic drug phenytoin , carbamazepine trileptal enrol Group B patient meet eligibility criterion enzyme inducer , enter Group A . As December 2005 , three DLT 's observed dose level 1 determine tolerable dose . A third dose level add use low dose Group A patient . Twelve patient entered third dose level Group A .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<criteria>INCLUSION CRITERIA : Patients histologically prove malignant glioma eligible protocol . Malignant glioma include glioblastoma multiforme ( GBM ) , anaplastic astrocytoma ( AA ) , anaplastic oligodendroglioma ( AO ) , anaplastic mixed oligoastrocytoma ( AMO ) , malignant glioma NOS ( otherwise specify ) . Additionally , patient primitive neuroectodermal tumor ( PNETs ) central nervous system , progressive lowgrade glioma radiographically diagnose brain stem gliomas refractory standard treatment eligible . Patients must unequivocal evidence tumor progression MRI CT scan . This scan perform within 14 day prior registration steroid dosage stable least 5 day . If steroid dose increase date image registration new baseline MR/CT require . The type scan , i.e. , MRI CT must use throughout period protocol treatment tumor measurement . Patients undergone recent resection recurrent progressive tumor eligible long follow condition apply : 1 . &lt; TAB &gt; They recover effect surgery . 2 . &lt; TAB &gt; Residual disease follow resection recurrent tumor mandate eligibility study . To best assess extent residual disease postoperatively , CT/ MRI do : later 96 hour immediate postoperative period least 4 week postoperatively , within 14 day registration , steroid dosage stable least 5 day . If 96 hour scan 14 day registration , scan need repeat . If steroid dose increase date imaging registration , new baseline MRI/CT require stable steroid dosage least 5 day . Patients must fail prior radiation therapy must interval great equal 4 week completion radiation therapy study entry . All patient must sign informed consent indicate aware investigational nature study . Patients must great equal 18 year old , life expectancy great 8 week . Patients must Karnofsky performance status great equal 60 . Patients must recover toxic effect prior therapy : 2 week noncytotoxic investigational agent , 4 week prior cytotoxic therapy , two week vincristine , 6 week nitrosoureas , 3 week procarbazine administration , 1 week noncytotoxic agent , e.g. , interferon , tamoxifen , thalidomide , cisretinoic acid , etc . ( radiosensitizer count ) . Any question relate definition noncytotoxic agent direct Study Chair . Patients must adequate bone marrow function ( WBC great equal 3,000/micro l , ANC great equal 1,500/mm ( 3 ) , platelet count great equal 100,000/mm ( 3 ) , hemoglobin great equal to10 gm/dl ) , adequate liver function ( SGOT bilirubin less equal 2 time ULN ) , adequate renal function ( creatinine less equal 1.5 mg/dL and/or creatinine clearance great equal 60 cc/min ) start therapy . These test must perform within 14 day prior registration . Eligibility level hemoglobin may reach transfusion . Patients must significant medical illness investigator 's opinion adequately control appropriate therapy would compromise patient ' ability tolerate therapy This study design include woman minority , design measure difference intervention effect . Males female recruit preference gender . No exclusion study base race . Minorities actively recruit participate . Patients must practice adequate contraception . Prior treatment enzyme induce antiepileptic drug must discontinue least 14 day prior study entry Group A patient . EXCLUSION CRITERIA : Patients , view treat physician , significant active cardiac , hepatic , renal disease ineligible . No concurrent use standard chemotherapeutics investigative agent . &lt; TAB &gt; Patients know active malignancy ( except nonmelanoma skin cancer carcinoma insitu cervix ) . Patients active infection require IV antibiotic . Patients pregnant breast feed . Patients disease obscure toxicity dangerously alter drug metabolism . QTc Bazett 's correction unmeasurable , great equal 460 msec screen ECG . If patient QTc great equal 460 msec screen ECG , second screen ECG may repeat least 24 hour apart . The average QTc 2 screen ECGs must less 460 msec order patient eligible study . EKG demonstrate clincically significant arrythmia ( multifocal premature ventricular contraction [ PVC ] , bigeminy , trigeminy , ventricular tachycardia , bradycardia ) symptomatic require treatment ( CTCAE grade 3 ) , asymptomatic sustain ventricular tachycardia . Patients baseline EKGs suggestive past present cardiac ischemia eligible unless appropriate ( defined P.I . trial ) negative cardiac work ( i.e . echocardiogram , stress test ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 1, 2014</verification_date>
	<keyword>Brain</keyword>
	<keyword>Tumor</keyword>
	<keyword>Malignant</keyword>
	<keyword>Therapy</keyword>
	<keyword>Progression</keyword>
	<keyword>Malignant Brain Tumor</keyword>
	<keyword>Malignant Glioma</keyword>
	<keyword>Glioma</keyword>
</DOC>